Adolescents and young adults are increasingly using GLP-1 receptor agonists for weight management, raising concerns among ...

The PIL seeks a ban on the marketing and distribution of specific GLP-1 receptor agonist (RA) drugs, namely Semaglutide, ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

AFTER losing three stone on fat jabs, Emmie Barwise loved nothing more than picking out a stylish outfit to showcase her svelte new figure. However, there was one accessory she wasn’t expecting to ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

Discover a recent report that states that, although GLP-1 medicines are generally well tolerated, there have been cases of ...

In its order, CJ Upadhyaya-led bench directed PIL litigant to submit to CDSCO the scientific studies and data relied upon in ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...